Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma N/A Complete
Inqovi Decitabine-Cedazuridine Myelodysplastic Syndromes (MDS) Reimburse with clinical criteria and/or conditions Complete
Inrebic fedratinib Myelofibrosis Reimburse with clinical criteria and/or conditions Complete
Inspiolto Respimat Tiotropium / olodaterol Chronic obstructive pulmonary disease List with criteria/condition Complete
Inspra Eplerenone Heart failure, NYHA class II Do not list at the submitted price Complete
Inspra Eplerenone Post myocardial infarction Do not list Complete
Intelence Etravirine HIV List with clinical criteria and/or conditions Complete
Intrarosa prasterone Postmenopausal vulvovaginal atrophy Reimburse with clinical criteria and/or conditions Complete
Intuniv XR Guanfacine hydrochloride Attention-deficit/hyperactivity disorder (ADHD) Do not list Complete
Invega Paliperidone Schizophrenia Do not list Complete